HC Wainwright Issues Negative Forecast for INKT Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Stock analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for MiNK Therapeutics in a research note issued to investors on Tuesday, March 18th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.63) per share for the quarter, down from their previous forecast of ($0.51). HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.32) EPS and FY2029 earnings at $0.12 EPS.

MiNK Therapeutics Stock Up 8.2 %

NASDAQ INKT opened at $9.10 on Friday. The firm has a market cap of $36.09 million, a price-to-earnings ratio of -2.33 and a beta of 0.16. The business has a 50-day moving average price of $8.96 and a 200-day moving average price of $7.76. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $19.00.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.12).

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.